| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.26 | 5e-15 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.25 | 6e-13 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.22 | 9e-12 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.23 | 9e-11 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.21 | 2e-09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.26 | 3e-08 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.27 | 5e-07 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.18 | 6e-07 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.2 | 3e-06 |